Alison Green
Dr Alison Green is a clinical biochemist with extensive experience in the development and evaluation of diagnostics tests for neurodegenerative disease, particularly Creutzfeldt-Jakob disease (CJD), Parkinson’s disease (PD) and Lewy body dementia (LBD). She gained a PhD from the University of London investigating the role brain-specific biomarkers in the diagnosis of dementia, before moving to The National CJD Research & Surveillance Unit at the University of Edinburgh. Whilst there she developed a Real-time Quaking Induced Conversion (RT-QuIC) assay for sporadic CJD, which was accepted into clinical practice in 2017. In 2016 she published the first report of a RT-QuIC assay for detection of alpha-synuclein in Lewy body dementia and Parkinson’s disease. Since that time the SAA (alpha-synuclein seed amplification assay) has been shown to be a robust and reliable diagnostic test for PD and LBD. Her subsequent publications have reported on the utility of SAAs in REM sleep behaviour disorder, atypical Parkinson’s disease and in LRRK2 associated PD.
Alison is currently working at Scottish Brain Sciences, Edinburgh on evaluating the clinical utility of the newly emerging blood tests for Alzheimer’s disease.